WuXi XDC Enters into Partnership with Multitude and HySlink Therapeutics
Shortly after its spinoff and IPO, WuXi Biologics’ subsidiary WuXi XDC has locked up a major customer on its quest to establish itself as a premier bioconjugation contract research, development and manufacturing organization.
WuXi XDC, which spun off from WuXi Bio And WuXi STA in November, has forged a partnership with the South Korean biotech IntoCell.
SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and IntoCell, a Korean biotechnology company dedicated to developing novel ADC platform technologies, announced today that they have signed a Memorandum of Understanding (MOU) for a comprehensive partnership in drug-linker technology and CRDMO services spanning from discovery to commercialization.
WuXi XDC Named Best CDMO Winner at 2023 World ADC Awards